Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 extension study of bimatoprost SR for long-term safety and durability in open-angle glaucoma or ocular hypertension
MOH_2020-01-06_008595Phase 3Recruiting
- Sponsor
- Allergan
- Start
- Nov 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bimatoprost in open-angle glaucoma (OAG) and ocular hypertension, sponsored by Allergan. Primary endpoints: Long-term safety and Duration of intraocular pressure-lowering effect. Started Nov 2018; status: recruiting.
02
Drugs
bimatoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on MOH_2020-01-06_008595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-01-06_008595.